0001209191-21-043741.txt : 20210629
0001209191-21-043741.hdr.sgml : 20210629
20210629181112
ACCESSION NUMBER: 0001209191-21-043741
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210604
FILED AS OF DATE: 20210629
DATE AS OF CHANGE: 20210629
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kuhn Rebecca
CENTRAL INDEX KEY: 0001855659
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40337
FILM NUMBER: 211059507
MAIL ADDRESS:
STREET 1: C/O NEUROPACE INC
STREET 2: 455 N. BERNARDO AVENUE
CITY: MOUTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NeuroPace Inc
CENTRAL INDEX KEY: 0001528287
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 223550230
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 455 N. BERNARDO AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
BUSINESS PHONE: 6502372700
MAIL ADDRESS:
STREET 1: 455 N. BERNARDO AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2021-06-04
2021-06-08
0
0001528287
NeuroPace Inc
NPCE
0001855659
Kuhn Rebecca
455 N. BERNARDO AVENUE
MOUNTAIN VIEW
CA
94043
0
1
0
0
Chief Financial Officer
Common Stock
2021-06-04
4
A
0
8310
0.00
A
11536
D
Stock Option (Right to Buy)
21.67
2021-06-04
4
A
0
16620
0.00
A
2021-06-04
2031-06-03
Common Stock
16620
16620
D
Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on April 22, 2022 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter.
25% of the shares subject to the option vest on April 22, 2022. The remaining shares subject to the option vest in twelve (12) equal quarterly installments thereafter. The option is early exercisable.
This amendment to Form 4 is being filed to correct (a) the amount of RSUs acquired and the amount of securities shares beneficially owned directly by the Reporting Person following the transaction in Table I, and (b) the amount of options acquired and the amount of options of this class beneficially owned directly by the Reporting Person following the transaction in Table II.
/s/ Mark B. Weeks, Attorney-in-Fact
2021-06-29